BIO-TECHNE (TECH) executive reports RSU exercise, tax withholding and corrected holdings
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
BIO-TECHNE Corp executive Steven C. Crouse reported routine equity compensation activity and updated holdings. On June 2, 2026, he exercised 600 restricted stock units into an equal number of common shares and had 216 shares of common stock withheld at $49.77 per share to satisfy tax obligations. Following the tax withholding, he directly held 6,761 shares of common stock. The filing also lists multiple outstanding stock options and restricted stock unit awards with exercise prices between $48.61 and $120.46 per share and expirations through 2036, indicating a substantial remaining equity position. A footnote states that a mathematical error in a prior Form 4 increased the reported beneficial ownership by 40 shares, and this filing reflects the corrected total.
Positive
- None.
Negative
- None.
Insider Trade Summary
600 shares exercised/converted
Mixed
18 txns
Insider
Crouse Steven C.
Role
President - Diag & Spatial Bi
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Restricted Stock Units | 600 | $0.00 | -- |
| Exercise | Common Stock | 600 | $0.00 | -- |
| Tax Withholding | Common Stock | 216 | $49.77 | $11K |
| holding | Restricted Stock Units | -- | -- | -- |
| holding | Restricted Stock Units | -- | -- | -- |
| holding | Restricted Stock Units | -- | -- | -- |
| holding | Restricted Stock Units | -- | -- | -- |
| holding | Stock Option (right to buy) | -- | -- | -- |
| holding | Stock Option (right to buy) | -- | -- | -- |
| holding | Stock Option (right to buy) | -- | -- | -- |
| holding | Stock Option (right to buy) | -- | -- | -- |
| holding | Stock Option (right to buy) | -- | -- | -- |
| holding | Stock Option (right to buy) | -- | -- | -- |
| holding | Stock Option (right to buy) | -- | -- | -- |
| holding | Stock Option (right to buy) | -- | -- | -- |
| holding | Performance Restricted Stock Units | -- | -- | -- |
| holding | Restricted Stock Units | -- | -- | -- |
| holding | Stock Option (right to buy) | -- | -- | -- |
Holdings After Transaction:
Restricted Stock Units — 1,200 shares (Direct, null);
Common Stock — 6,977 shares (Direct, null);
Stock Option (right to buy) — 3,856 shares (Direct, null);
Performance Restricted Stock Units — 2,387 shares (Direct, null)
Footnotes (1)
- Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. 794 restricted stock units vest on 5/1/2027. 600 restricted stock units vest on each of 6/2/2026, 6/2/2027 and 6/2/2028. 1,379 restricted stock units vest on 8/15/2026. 1,868 restricted stock units vest on 8/15/2026 and 1,869 restricted stock units vest on 8/15/2027. 2,176 restricted stock units vest on each of 8/15/2026 and 8/15/2028; and 2,177 restricted stock units vest on 8/15/2027. 100% vested. Options to purchase 6,140 shares vest on each of 8/15/2023, 8/15/2024, 8/15/2025 and 8/15/2026. Options to purchase 3,162 shares vest on each of 8/15/2024, 8/15/2026 and 8/15/2027; and options to purchase 3,163 shares vest on 8/15/2025. Options to purchase 1,832 shares vest on each of 5/1/2025, 5/1/2026 and 5/1/2028; and options to purchase 1,831 shares vest on 5/1/2027. Options to purchase 4,283 shares vest on each of 8/15/2025, 8/15/2027 and 8/15/2028; and options to purchase 4,284 shares vest on 8/15/2026. Options to purchase 1,359 shares vest on each of 6/2/2026 and 6/2/2028; and options to purchase 1,358 shares vest on each of 6/2/2027 and 6/2/2029. Options to purchase 4,788 shares vest on each of 8/15/2026, 8/15/2027 and 8/15/2029; and options to purchase 4,787 shares vest on 8/15/2028. Vests in full or in part on 8/15/2028 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). 245 restricted stock units vest on 3/2/2027, 3/2/2028 and 3/2/2029. Options to purchase 478 shares vest on each of 3/2/2027, 3/2/2028 and 3/2/2030; and options to purchase 477 shares vest on 3/2/2029. Due to a mathematical error on the Form 4 filed May 5, 2026, the number of shares beneficially owned is being increased by 40 shares and this filing represents the correct number of shares beneficially owned by the Reporting Person.
Key Figures
RSUs exercised: 600 shares
Tax-withholding shares: 216 shares at $49.77
Common shares held: 6,761 shares
+5 more
8 metrics
RSUs exercised
600 shares
Restricted stock units converted to common stock on June 2, 2026
Tax-withholding shares
216 shares at $49.77
Common stock withheld to cover tax liabilities on June 2, 2026
Common shares held
6,761 shares
Direct holdings after tax withholding transaction on June 2, 2026
Option exercise price
$53.60/share
Stock option on common stock expiring August 15, 2035
Option exercise price
$57.82/share
Stock option on common stock expiring March 2, 2036
Largest option block
24,560 underlying shares
Stock option at $94.52/share expiring August 15, 2029
Performance RSUs outstanding
2,387 units
Performance restricted stock units on common stock as reported
Correction to holdings
40 shares
Increase in beneficially owned shares due to prior mathematical error
Key Terms
Restricted Stock Units, Performance Restricted Stock Units, Stock Option (right to buy), tax-withholding disposition, +1 more
5 terms
Restricted Stock Units financial
"Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock."
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
Performance Restricted Stock Units financial
"Performance Restricted Stock Units with 2,387 underlying shares of common stock are reported as derivative holdings."
Performance restricted stock units (PRSUs) are promises to deliver company shares to employees or executives only if the business meets specific performance targets and any time-based holding rules. Think of them as a bonus that converts into stock only after set goals are reached, so investors watch PRSUs for two reasons: they can dilute existing shares if paid out, and they signal how closely management’s pay is tied to company performance.
Stock Option (right to buy) financial
"Stock Option (right to buy) on common stock with exercise prices such as 53.6000 and 57.8200 is listed."
tax-withholding disposition financial
"Payment of exercise price or tax liability by delivering securities is described as a tax-withholding disposition."
A tax-withholding disposition is an event or transaction—such as selling or transferring securities, exercising options, or receiving compensation—that triggers a requirement to hold back part of the payment and remit it to tax authorities. It matters to investors because it reduces the cash they receive immediately and can change the timing and amount of taxable income, like a cashier taking a portion of your sale proceeds to pay taxes before you get the rest.
beneficially owned financial
"the number of shares beneficially owned is being increased by 40 shares and this filing represents the correct number"
Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.
FAQ
What insider transactions did BIO-TECHNE (TECH) report for Steven C. Crouse?
BIO-TECHNE reported that executive Steven C. Crouse exercised 600 restricted stock units into common shares and had 216 common shares withheld to cover tax obligations. The filing mainly updates his holdings and outstanding equity awards, reflecting routine compensation-related activity.
Did Steven C. Crouse exercise any derivatives or RSUs in BIO-TECHNE (TECH)?
Yes. The Form 4 reports that 600 restricted stock units were exercised or converted into 600 shares of BIO-TECHNE common stock. This is recorded with transaction code M, indicating a derivative exercise or conversion, typical of equity compensation vesting.
What outstanding stock options does Steven C. Crouse have in BIO-TECHNE (TECH)?
The filing lists several stock option awards on BIO-TECHNE common stock, including options with exercise prices such as $53.60, $57.82, $73.46, and $120.46 per share. These options have expiration dates ranging from 2028 through 2036, reflecting long-term equity incentives.